The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Sanofi's Q3 earnings surged, with a 14.4% increase in income to €4.61 billion, led by Dupixent and new launches. Revenue beat ...

Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for ...

The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

This content was published on Oct 26, 2024 The Swiss Federal Democratic Union (EDU) has handed in referendum signatures to seek a vote to prevent the Eurovision Song Contest (ESC) from taking ...

Hi, it’s Aaron Kirchfeld, Pamela Barbaglia, Dinesh Nair and Swetha Gopinath in London, looking at how Europe's biggest buyout ...

(Goldman, 10/24) Bloomberg: How Sanofi's Sale Of Consumer Pharma Arm Opella Turned Into A Brawl After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision ...

After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision to sell its over-the-counter business to a US buyout firm descended into mudslinging, public ...